Litigation Watch: ARTHRITIS DRUGS is a monthly newsletter for attorneys, focusing on drugs used to treat osteo and rheumatoid arthritis: Arava, Enbrel, Remicade, Humira, Vioxx, Celebrex and more. These drugs are already the subject of litigation following claims that they cause everything from liver damage to cancer, heart failure and strokes. Each issue features case news, interviews, legislative and FDA updates, and reviews from current medical literature.
Arthritis Drugs - Issue: 39
Pfizer Shareholders Failed to Adequately Plead Demand Futility, Judge Says
Merck Seeks Sanctions Against Plaintiffs' Counsel for Discovery Violations
Merck Files Brief in Garza Appeal, Says Causation Evidence Insufficient
3rd Circuit Revives Shareholders' Claims that Merck Hid Vioxx Risks
Federal Bextra, Celebrex Plaintiffs Can Pursue False Advertising Claims
Merck Says Evidence Insufficient for Remittitur, Requests New Trial
Merck Moves for Interlocutory Review of MDL Order Rejecting Preemption
Arthritis Drugs - Issue: 38
7th Circuit Finds Causation Evidence Unreliable in Remicade Action
